



Thursday, November 19, 2015
7:15 a.m. to 8:45 a.m.
Cannon Health Building
Room 128

Committee Members Present:

Bryan Larson, PharmD
Clinton Sheffield, MD
Clayton Grace, RPh

Beth Young, PharmD
Beth Johnson, RPh
Jameson Rice, PharmD

Committee Members Excused:

Ellie Brownstein, MD

Keith Tolman, MD

Dept. of Health/Div. of Health Care Financing Staff Present:

Robyn Seely, PharmD
Merelynn Berrett, RN

Chad Hope, PharmD

University of Utah Drug Regimen Review Center Staff Present:

Melissa Archer, PharmD

Other Individuals Present:

Gary Oderda, UofU
Vicki Frydrych, UofU
Joann Brammer, Valley Behavioral Health
Susan Siegfried, DUR Board

David Malmrose, UofU
Cody Ball, Select Health
Todd Thatcher, Valley Behavioral Health

Meeting conducted by: Clinton Sheffield, MD

1. **Welcome & Housekeeping:** Clinton Sheffield opened the meeting and welcomed Clayton Grace, a new member of the committee and an independent pharmacist.
2. **Review and Approval of October Minutes:** Clinton Sheffield made a motion to approve the minutes from October. Bryan Larson seconded the motion. All in favor.
3. **Review and Approval of Amended March Minutes:** Bryan Larson gave background of the previously approved minutes compared to the audio recording and proposed amended minutes. Bryan Larson made a motion to approve the amended minutes from March. Clinton Sheffield seconded the motion. All in favor.
4. **Drug Utilization Review (DUR) Board update:** The DUR board continued their review of PCSK-9 agents: Praluent (alirocumab) and Repatha (evolocumab) at the last meeting.

Prior Authorization criteria were discussed and established by the DUR Board.

5. **Ophthalmic Beta Adrenergic Antagonists:** Melissa Archer presented a review of the Ophthalmic Beta Adrenergic Antagonists. She presented peer-reviewed research regarding the safety and efficacy of each agent, clinical trials, disease-state treatment guidelines and Utah Medicaid utilization data.
6. **Moran Eye Center:** Alan Crandall – He presented information about the ophthalmic beta blockers and was available to answer questions.
7. **Board Discussion**
 - a. Bryan Larson asked Dr. Crandall about perfect use compared to actual use of these agents.
 - b. Alan Crandall discussed the importance of proper adherence to these agents and the importance of access to different agents in different clinical situations.
 - c. Bryan Larson clarified the PA process and that access remains available to Medicaid beneficiaries even for non-preferred agents after failure with a preferred agent. He also discussed grandfathering and its applicability to patients already taking an agent added as non-preferred
 - d. Chad Hope further clarified the way that different tiers of supplemental rebate offers affect the PDL.
 - e. Beth Johnson made a motion to add the presented class as equally safe and effective and that at least one combination agent should be preferred. Patients already taking an agent in this class should be grandfathered to allow them to continue therapy. Clinton Sheffield seconded the motion. All in favor.
8. **Ophthalmic Cholinergic Agonists:** Melissa Archer presented a review of the Ophthalmic Cholinergic Agonists. She presented peer-reviewed research regarding the safety and efficacy of each agent, clinical trials, disease-state treatment guidelines and Utah Medicaid utilization data.
9. **Moran Eye Center:** Alan Crandall – He presented information about the ophthalmic cholinergic agonists and was available to answer questions.
10. **Board Discussion**
 - a. Clinton Sheffield asked about the differences between formulations of these agents.
 - b. Alan Crandall answered that pilocarpine is probably used in less than 1% of glaucoma cases. It is dosed four times daily and is associated with significant adverse effects, including substantial myopia. He also discussed acetylcholine and carbachol and their use in ophthalmic surgery; particularly cataract surgery, but also mentioned that these agents would not be used in an outpatient setting.
 - c. Chad Hope clarified that regardless of whether acetylcholine and carbachol are equally safe and effective, they will likely never be dispensed in an outpatient pharmacy.
11. **Other State Report:** Bryan Larson reported PDL listings for agents in this class in other States Medicaid programs.
12. **Board Discussion**
 - a. Clinton Sheffield asked about phospholine.

- b. Alan Crandall answered that it is incredibly powerful and has significant adverse effects, but serves as a drug of last resort in rare cases. He also said that practitioners had to practically beg Alcon to continue manufacturing phospholine for use in these rare cases.
- c. Clinton Sheffield made a motion to add the pilocarpine to the PDL as a preferred agent. Beth Johnson seconded the motion. All in favor.

13. Meeting Adjourned

- 14. Next meeting is scheduled for December 17, 2015. Agents for Opioid Induced Constipation will be discussed.

Minutes prepared by Bryan S. Larson

Recording available upon request, send email to medicaidpharmacy@utah.gov